-
Next-generation patient models for colorectal cancer research Nat. Biotechnol. (IF 33.1) Pub Date : 2024-07-02
-
High-throughput discovery of MHC class I- and II-restricted T cell epitopes using synthetic cellular circuits Nat. Biotechnol. (IF 33.1) Pub Date : 2024-07-02 Ayano C. Kohlgruber, Mohammad H. Dezfulian, Brandon M. Sie, Charlotte I. Wang, Tomasz Kula, Uri Laserson, H. Benjamin Larman, Stephen J. Elledge
-
Tracking-seq reveals the heterogeneity of off-target effects in CRISPR–Cas9-mediated genome editing Nat. Biotechnol. (IF 33.1) Pub Date : 2024-07-02 Ming Zhu, Runda Xu, Junsong Yuan, Jiacheng Wang, Xiaoyu Ren, Tingting Cong, Yaxian You, Anji Ju, Longchen Xu, Huimin Wang, Peiyuan Zheng, Huiying Tao, Chunhua Lin, Honghao Yu, Juanjuan Du, Xin Lin, Wei Xie, Yinqing Li, Xun Lan
-
Patient-derived mini-colons enable long-term modeling of tumor–microenvironment complexity Nat. Biotechnol. (IF 33.1) Pub Date : 2024-07-02 L. Francisco Lorenzo-Martín, Nicolas Broguiere, Jakob Langer, Lucie Tillard, Mikhail Nikolaev, George Coukos, Krisztian Homicsko, Matthias P. Lutolf
-
CRISPR screens of tumor-infiltrating NK cells identify genetic checkpoints for CAR-NK therapy Nat. Biotechnol. (IF 33.1) Pub Date : 2024-06-25
-
Increasing access to biotech products for animal agriculture in Sub-Saharan Africa through partnerships Nat. Biotechnol. (IF 33.1) Pub Date : 2024-06-25 José de la Fuente, Christian Gortázar, Marinela Contreras, Frederick Kabi, Paul Kasaija, Swidiq Mugerwa, Justus Rutaisire
-
In vivo AAV–SB-CRISPR screens of tumor-infiltrating primary NK cells identify genetic checkpoints of CAR-NK therapy Nat. Biotechnol. (IF 33.1) Pub Date : 2024-06-25 Lei Peng, Paul A. Renauer, Giacomo Sferruzza, Luojia Yang, Yongji Zou, Zhenghao Fang, Jonathan J. Park, Ryan D. Chow, Yueqi Zhang, Qianqian Lin, Meizhu Bai, Angelica Sanchez, Yongzhan Zhang, Stanley Z. Lam, Lupeng Ye, Sidi Chen
-
Machine learning prediction of prime editing efficiency across diverse chromatin contexts Nat. Biotechnol. (IF 33.1) Pub Date : 2024-06-21 Nicolas Mathis, Ahmed Allam, András Tálas, Lucas Kissling, Elena Benvenuto, Lukas Schmidheini, Ruben Schep, Tanav Damodharan, Zsolt Balázs, Sharan Janjuha, Eleonora I. Ioannidi, Desirée Böck, Bas van Steensel, Michael Krauthammer, Gerald Schwank
-
Effects of the first successful lawsuit against a consumer neurotechnology company for violating brain data privacy Nat. Biotechnol. (IF 33.1) Pub Date : 2024-06-20 José M. Muñoz, José Ángel Marinaro, José Antonio Iglesias, Moisés Sánchez, Natalia Monti, Ciro Colombara, Guido Girardi
On 9 August 2023 the Supreme Court of Chile (SCC) ruled in favor of former senator Guido Girardi in a constitutional protection appeal filed against the neurotechnology company Emotiv1 for violating his rights to privacy and psychological integrity, which are enshrined in Article 19 of Chile’s constitution2. The authors of the present piece — the plaintiff, some of his lawyers and legal advisers, and
-
Editor’s pick: Tenpoint Therapeutics Nat. Biotechnol. (IF 33.1) Pub Date : 2024-06-19
Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Tenpoint Therapeutics optimizes delivery and generation of stem-cell-derived retinal cells for vision repair.
-
Tracking gene order provides a new perspective on intraspecific evolution in microbiotas Nat. Biotechnol. (IF 33.1) Pub Date : 2024-06-19
-
Editor’s pick: Tome Biosciences Nat. Biotechnol. (IF 33.1) Pub Date : 2024-06-19
Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Tome Biosciences inserts large DNA sequences into precise genomic locations, overcoming limitations of base and prime editing.
-
Strain tracking in complex microbiomes using synteny analysis reveals per-species modes of evolution Nat. Biotechnol. (IF 33.1) Pub Date : 2024-06-19 Hagay Enav, Inbal Paz, Ruth E. Ley
-
Engineered yeast produces the plant-based vaccine adjuvant QS-21 Nat. Biotechnol. (IF 33.1) Pub Date : 2024-06-17 Iris Marchal
Extracting pharmacological compounds from plants can be ecologically damaging and often results in low yields, which limits their broad use. For instance, the supply of the potent vaccine adjuvant QS-21 is dependent on laborious extraction from the bark of the Chilean soapbark tree. Writing in Nature, Liu et al. describe an alternative method to produce QS-21 and its derivatives at scale using engineered
-
OpenFold provides insights into AlphaFold2’s learning behavior Nat. Biotechnol. (IF 33.1) Pub Date : 2024-06-17 Iris Marchal
Despite the immense utility of AlphaFold2 in predicting protein structure, the official implementation excludes code for its training procedure and the associated required data. This makes it difficult to study the model’s learning behavior and to create variants that can perform new tasks. Writing in Nature Methods, AlQuraishi and colleagues now report OpenFold, a trainable and open-source implementation
-
Honey without bees Nat. Biotechnol. (IF 33.1) Pub Date : 2024-06-17
Honey has been a prized food since ancient times. A complex blend of sugars, mostly fructose and glucose, and small amounts of other sugars, proteins, amino acids, vitamins and minerals, honey is a $8.94 billion market, and its popularity continues to grow. But over the last decade, honeybees (Apis mellifera) have been hindered from making this natural product by disappearing grassland, herbicides
-
A vaccine strategy for inducing broadly neutralizing antibodies against HIV Nat. Biotechnol. (IF 33.1) Pub Date : 2024-06-17 Iris Marchal
An effective HIV vaccine must induce broadly neutralizing antibodies (bnAbs) that target the most conserved sites of the HIV envelope, a feat that has not yet been achieved in humans. Germline-targeting vaccine design holds promise by using immunogens to prime naive B cells for bnAb precursor activation and then boosting their maturation. A major challenge for this approach is that antibody–antigen
-
First-in-class T cell engager approved for lung cancer Nat. Biotechnol. (IF 33.1) Pub Date : 2024-06-17
Amgen’s T cell engager Imdelltra (tarlatamab) has gained FDA accelerated approval for an aggressive type of cell lung cancer that is notoriously difficult to treat. The bispecific antibody is designed to bind both delta-like ligand 3 (DLL3) on small cell lung cancer (SCLC) cells and CD3 on T cells. Pharma companies have long considered DDL3 a promising target in oncology because healthy cells express
-
Forum: Anikeeva, Courtine and Bloch Nat. Biotechnol. (IF 33.1) Pub Date : 2024-06-17
On this episode, Chief Editor Barbara Cheifet speaks with Polina Anikeeva from MIT, Grégoire Courtine from EPFL, and Jocelyn Bloch, a neurosurgeon at Lausanne University Hospital. These three leaders in the field of neurotechnologies discuss new devices that help us learn how our brain works, implantable brain–computer interfaces that are helping patients with neurological disorders walk again, and
-
Biotech news from around the world Nat. Biotechnol. (IF 33.1) Pub Date : 2024-06-17
The kingdom pledges $500 million to the Bill & Melinda Gates Foundation to help fight polio. The funding, which helps close the funding gap in the $4.8 billion budget for the Global Polio Eradication Initiative, will be spread out over five years and makes Saudi Arabia one of the biggest national donors, along with the United States. A pilot project by the government of New South Wales has produced
-
Gene therapy restores hearing Nat. Biotechnol. (IF 33.1) Pub Date : 2024-06-17
Regeneron Pharmaceuticals has released preliminary data from the first two patients treated with the investigational gene therapy DB-OTO. At the American Society for Gene and Cell Therapy (ASGCT) annual meeting in May, the company disclosed that, during the CHORD clinical trial, designed to evaluate safety and tolerability, the gene therapy improved hearing in two children with profound genetic deafness
-
Cancer diagnostics Nat. Biotechnol. (IF 33.1) Pub Date : 2024-06-17
Recent patents relating to systems and methods for cancer detection and diagnosis.
-
Bird flu in wastewater Nat. Biotechnol. (IF 33.1) Pub Date : 2024-06-17
The Centers for Disease Control and Prevention (CDC) is testing wastewater across the United States to track the spread of influenza virus, including the avian influenza A virus H5N1 outbreak. The CDC and its partners are sampling wastewater from 689 sites to detect influenza A virus by quantitative PCR. The surveillance and reporting system also includes monkeypox and SARS-CoV-2. Data from May 5–18
-
B cells as drug factories Nat. Biotechnol. (IF 33.1) Pub Date : 2024-06-17
Companies are engineering B cells to produce gene-encoded medicines, but clinical proof of concept is needed to convince the doubters that this platform can deliver.
-
People Nat. Biotechnol. (IF 33.1) Pub Date : 2024-06-17
Recent moves of note in and around the biotech and pharma industries.
-
Barriers and enablers to the effective implementation of omics research in low- and middle-income countries Nat. Biotechnol. (IF 33.1) Pub Date : 2024-06-17 Jacus S. Nacis, Patrick Kamande, Alemayehu Teklu Toni, Evans Mudibo, Robert Musyimi, Siam Popluechai, Trenton Dailey-Chwalibóg, Wieger Voskuijl, Genevieve Dable-Tupas, Abu Sadat Mohammad Sayeem Bin Shahid, Neil Andrew Bascos, Farzana Afroze, Mohammod Jobayer Chisti, Benson Singa, Moses Ngari, Caroline Tigoi, Gomezgani Mhango, Harry Freitag, Isabel Potani, John Mukisa, Amir Kirolos, Kuda Mutasa, Lionel
-
The sufficiency of disclosure of medical artificial intelligence patents Nat. Biotechnol. (IF 33.1) Pub Date : 2024-06-17 Mateo Aboy, W. Nicholson Price, Seth Raker, Kathleen Liddell
-
Precision radiation opens a new window on cancer therapy Nat. Biotechnol. (IF 33.1) Pub Date : 2024-06-12
-
Crowd-sourced benchmarking of single-sample tumor subclonal reconstruction Nat. Biotechnol. (IF 33.1) Pub Date : 2024-06-11 Adriana Salcedo, Maxime Tarabichi, Alex Buchanan, Shadrielle M. G. Espiritu, Hongjiu Zhang, Kaiyi Zhu, Tai-Hsien Ou Yang, Ignaty Leshchiner, Dimitris Anastassiou, Yuanfang Guan, Gun Ho Jang, Mohammed F. E. Mootor, Kerstin Haase, Amit G. Deshwar, William Zou, Imaad Umar, Stefan Dentro, Jeff A. Wintersinger, Kami Chiotti, Jonas Demeulemeester, Clemency Jolly, Lesia Sycza, Minjeong Ko, David C. Wedge
-
Cis-editing for all Nat. Biotechnol. (IF 33.1) Pub Date : 2024-06-06
CRISPR technologies offer new opportunities to democratize gene-edited crops and promote global sustainability.
-
High-yield porphyrin production through metabolic engineering and biocatalysis Nat. Biotechnol. (IF 33.1) Pub Date : 2024-06-05 Haihong Chen, Yaohong Wang, Weishan Wang, Ting Cao, Lu Zhang, Zhengduo Wang, Xuran Chi, Tong Shi, Huangwei Wang, Xinwei He, Mindong Liang, Mengxue Yang, Wenyi Jiang, Dongyuan Lv, Jiaming Yu, Guoliang Zhu, Yongtao Xie, Bei Gao, Xinye Wang, Xueting Liu, Youyuan Li, Limin Ouyang, Jingyu Zhang, Huimin Liu, Zilong Li, Yaojun Tong, Xuekui Xia, Gao-Yi Tan, Lixin Zhang
-
High-fidelity and fast 3D imaging of subcellular dynamics in native states Nat. Biotechnol. (IF 33.1) Pub Date : 2024-06-04
-
Next-generation psychedelics: should new agents skip the trip? Nat. Biotechnol. (IF 33.1) Pub Date : 2024-06-03
Companies attract venture funding for redesigned psychedelic drugs and notch clinical trial milestones.
-
Femtechs take on women’s health Nat. Biotechnol. (IF 33.1) Pub Date : 2024-05-29
An upsurge in biotechs focused on women’s health responds to a fresh understanding of female biology to develop new tools and treatments.
-
Trans-nuclease activity of Cas9 activated by DNA or RNA target binding Nat. Biotechnol. (IF 33.1) Pub Date : 2024-05-29 Jiyun Chen, Ying Chen, Linglong Huang, Xiaofeng Lin, Hong Chen, Wenwen Xiang, Liang Liu
-
Enhancing prime editing in hematopoietic stem and progenitor cells by modulating nucleotide metabolism Nat. Biotechnol. (IF 33.1) Pub Date : 2024-05-28 Sébastien Levesque, Andrea Cosentino, Archana Verma, Pietro Genovese, Daniel E. Bauer
-
Long-term intravital subcellular imaging with confocal scanning light-field microscopy Nat. Biotechnol. (IF 33.1) Pub Date : 2024-05-27 Zhi Lu, Siqing Zuo, Minghui Shi, Jiaqi Fan, Jingyu Xie, Guihua Xiao, Li Yu, Jiamin Wu, Qionghai Dai
-
Mapping variant effects on anti-tumor hallmarks of primary human T cells with base-editing screens Nat. Biotechnol. (IF 33.1) Pub Date : 2024-05-23 Zachary H. Walsh, Parin Shah, Neeharika Kothapalli, Shivem B. Shah, Gergo Nikolenyi, D. Zack Brodtman, Giuseppe Leuzzi, Meri Rogava, Michael Mu, Patricia Ho, Sinan Abuzaid, Neil Vasan, Mohammed AlQuraishi, Joshua D. Milner, Alberto Ciccia, Johannes C. Melms, Benjamin Izar
-
Mapping medically relevant RNA isoform diversity in the aged human frontal cortex with deep long-read RNA-seq Nat. Biotechnol. (IF 33.1) Pub Date : 2024-05-22 Bernardo Aguzzoli Heberle, J. Anthony Brandon, Madeline L. Page, Kayla A. Nations, Ketsile I. Dikobe, Brendan J. White, Lacey A. Gordon, Grant A. Fox, Mark E. Wadsworth, Patricia H. Doyle, Brittney A. Williams, Edward J. Fox, Anantharaman Shantaraman, Mina Ryten, Sara Goodwin, Elena Ghiban, Robert Wappel, Senem Mavruk-Eskipehlivan, Justin B. Miller, Nicholas T. Seyfried, Peter T. Nelson, John D. Fryer
-
Development of multiplexed orthogonal base editor (MOBE) systems Nat. Biotechnol. (IF 33.1) Pub Date : 2024-05-21 Quinn T. Cowan, Sifeng Gu, Wanjun Gu, Brodie L. Ranzau, Tatum S. Simonson, Alexis C. Komor
-
Advancing programmable gene expression in plants using CRISPRi-based Boolean gates Nat. Biotechnol. (IF 33.1) Pub Date : 2024-05-20
-
CRISPRi-based circuits to control gene expression in plants Nat. Biotechnol. (IF 33.1) Pub Date : 2024-05-20 Muhammad Adil Khan, Gabrielle Herring, Jia Yuan Zhu, Marina Oliva, Elliott Fourie, Benjamin Johnston, Zhining Zhang, Jarred Potter, Luke Pineda, Jahnvi Pflueger, Tessa Swain, Christian Pflueger, James P. B. Lloyd, David Secco, Ian Small, Brendan N. Kidd, Ryan Lister
-
Nanopore sequencing Nat. Biotechnol. (IF 33.1) Pub Date : 2024-05-17
Recent patents relating to devices and methods for the improvement of nanopore sequencing systems.
-
FDA clears prime editors for testing in humans Nat. Biotechnol. (IF 33.1) Pub Date : 2024-05-17
Biotech company Prime Medicine received a regulator’s green light to start testing its next-generation gene editing candidate in humans. On 29 April, the US Food and Drug Administration approved the biotech’s Investigational New Drug application, which gives Prime the go-ahead to test its first product candidate, PM359, in a phase 1/2 clinical trial in pediatric and adult patients with chronic granulomatosis
-
Industry moves on 3Rs Nat. Biotechnol. (IF 33.1) Pub Date : 2024-05-17
Charles River Laboratories is investing $500 million to promote the values of the 3Rs minimization of animal testing across its business. The Alternative Methods Advancement Project, launched in April, will receive $300 million over the next five years, adding to an initial $200 million invested so far by the contract research organization (CRO). The aim is to boost the implementation of 3Rs —replacement
-
A genetic rescue strategy for Timothy syndrome Nat. Biotechnol. (IF 33.1) Pub Date : 2024-05-17 Iris Marchal
Finding treatments for neurological disorders is challenging due to a lack of human brain tissue and an inability to recapitulate disease phenotypes in animal models. This is especially true for neurodevelopmental disorders, such as Timothy syndrome. Writing in Nature, Pașca and colleagues develop a rescue strategy for Timothy syndrome using only in vitro stem cell models and in vivo transplantation
-
From Bench to Podcast: Marcus Walker Nat. Biotechnol. (IF 33.1) Pub Date : 2024-05-17
With an informal and honest touch, Marcus and Cláudia dive behind the scenes of the paper. They range from the inspiration to combine microbiology and fashion, though what went wrong at the bench, all the way to the economical and environmental implications of living biomaterials. For all those who struggle with measuring optical density, this episode is for you!
-
Star-studded AI biotech launch Nat. Biotechnol. (IF 33.1) Pub Date : 2024-05-17
The latest biotech aiming to use AI to accelerate drug discovery emerged from stealth on 23 April flush with over $1 billion in venture capital. San Francisco–based Xaira Therapeutics envisions an end-to-end application of AI technologies, from applying fundamental computational methods for biological discovery, to de novo antibody generation, to managing human trials. The foundational technologies
-
Gut microbes may influence cardiovascular health Nat. Biotechnol. (IF 33.1) Pub Date : 2024-05-17 Iris Marchal
Previous studies have linked changes in the gut microbiome to cardiovascular disease, but the metabolic mechanisms that underlie these associations remain unexplored. Writing in Cell, Li et al. report extensive profiling of microbes and metabolites in patients with cardiovascular disease, identifying a cholesterol-metabolizing bacterium with potential health benefits. The authors collected stool samples
-
Biotech news from around the world Nat. Biotechnol. (IF 33.1) Pub Date : 2024-05-17
Vilnius-based biotech Caszyme opens a state-of-the-art 14,000-square-foot R&D facility to meet a growing regional demand for end-to-end CRISPR gene-editing solutions. Established in 2017, Caszyme has collaborated with multiple life science organizations aiming to enter the CRISPR field or expand their gene-editing capabilities. The Norwegian Cancer Society partners with Cancer Research UK on a multi-project
-
From Bench to Podcast: He, Jin and Shi Nat. Biotechnol. (IF 33.1) Pub Date : 2024-05-17
During their chat, Siyu He, Yinuo Jin and Lingting Shi, all at different stages of their academic paths, dig into the layers of Starfysh and its relevance to cancer research. They also share the struggles of peer review, the wonders of collaborative work and how this experience shaped their sure-to-be-fantastic academic careers. https://shows.acast.com/forum/from-bench-to-podcast-stories-from-biot
-
FOXO1 enhances CAR T cell fitness and function Nat. Biotechnol. (IF 33.1) Pub Date : 2024-05-17 Iris Marchal
CAR T cell therapies are limited by exhaustion of these cells in vivo, especially in treating solid tumors. Positive treatment responses have been associated with improved T cell fitness, but it is not known which transcription factors drive these fitness programs. Two papers published in Nature have now identified FOXO1 as a strong enhancer of CAR T cell function that boosts antitumor activity, memory
-
A second chance for plant biotechnology in Europe Nat. Biotechnol. (IF 33.1) Pub Date : 2024-05-17
Europe tilts towards gene-edited plants, but progress could be derailed over who owns the patents.
-
Biopharma foresees a ‘quantum advantage’: they could be right Nat. Biotechnol. (IF 33.1) Pub Date : 2024-05-17
Companies are betting on the power of quantum computing to simulate molecular dynamics, solve drug design and even accelerate clinical studies.
-
People Nat. Biotechnol. (IF 33.1) Pub Date : 2024-05-17
Recent moves of note in and around the biotech and pharma industries.
-
The impact of gender diversity on junior versus senior biomedical scientists’ NIH research awards Nat. Biotechnol. (IF 33.1) Pub Date : 2024-05-17 Christopher C. Liu, Beril Yalcinkaya, Andy S. Back, Waverly W. Ding
-
Overcoming unpredictability in biotech patents by tailored claiming aligned with genuine enablement Nat. Biotechnol. (IF 33.1) Pub Date : 2024-05-17 Ranjit S. Ranbhor
The unpredictability inherent to biological systems poses singular obstacles for biotechnology patents regarding the satisfaction of the enablement and written description requirements.
-
Decoding gene regulation with CRISPR perturbations Nat. Biotechnol. (IF 33.1) Pub Date : 2024-05-17 Stefan Oberlin, Michael T. McManus
-
Bidirectional epigenetic editing reveals hierarchies in gene regulation Nat. Biotechnol. (IF 33.1) Pub Date : 2024-05-17 Naomi M. Pacalin, Zachary Steinhart, Quanming Shi, Julia A. Belk, Dmytro Dorovskyi, Katerina Kraft, Kevin R. Parker, Brian R. Shy, Alexander Marson, Howard Y. Chang
-
Engineered CRISPR-Cas12a for higher-order combinatorial chromatin perturbations Nat. Biotechnol. (IF 33.1) Pub Date : 2024-05-17 C. C.-S. Hsiung, C. M. Wilson, N. A. Sambold, R. Dai, Q. Chen, N. Teyssier, S. Misiukiewicz, A. Arab, T. O’Loughlin, J. C. Cofsky, J. Shi, L. A. Gilbert